open access

Ahead of Print
Research paper
Published online: 2022-12-06
Get Citation

Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas

Shixiang Dong12, Fengsheng Yu1, Yutong Liu21, Xiao Yu1, Xin Sun1, Wenjie Wang1, Yankui Wang21
DOI: 10.5603/GP.a2022.0123
·
Pubmed: 36477777
Affiliations
  1. Department of Obstetrics and Gynecology, the Affiliated Hospital of Qingdao University, Qingdao, China
  2. Affiliated Hospital of Qingdao University, Qingdao, China

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2022-12-06

Abstract

Objectives: To compare the clinical characteristics and prognosis of women with clear cell versus high-grade serous ovarian carcinoma.

Material and methods: Retrospective analysis of the clinical data of 50 cases patients with ovarian clear cell carcinoma (OCCC) and 103 cases with high-grade serous ovarian carcinoma (HGSOC), who were initially treated and completed standardized therapy in Affiliated Hospital of Qingdao University from January 2013 to December 2017.

Results: There were significant differences in age, gravidity (G > 1), chief complaint, with ovarian endometriosis, tumor diameter, unilateral or bilateral, cystic and solid tumor, CA125, HE4, CA199, lactate dehydrogenase (LDH), and FIGO stage between the two groups. The differences in the prognosis between OCCC patients and HGSOC patients with early stage (FIGO I–II) were not statistically significant. The 5-year overall survival and progression-free survival of OCCC patients were significantly worse than those of HGSOC patients with advanced stage (FIGO III–IV) (p < 0.05). FIGO stage and non-R0 resection were independent risk factors affecting the prognosis of patients with ovarian clear cell carcinoma, screening by Cox regression analysis. FIGO stage, the lowest value of CA125, and non-R0 resection were independent risk factors affecting the prognosis of patients with high-grade serous ovarian cancer.

Conclusions: The clinical characteristics and prognosis of OCCC are different from those of HGSOC. Ovarian clear cell carcinoma (OCCC) patients have a significantly worse prognosis than those with HGSOC in the advanced stage (FIGO Ⅲ–Ⅳ). Satisfactory tumor resection is an essential factor related to the prognosis of patients with OCCC and HGSOC.

Abstract

Objectives: To compare the clinical characteristics and prognosis of women with clear cell versus high-grade serous ovarian carcinoma.

Material and methods: Retrospective analysis of the clinical data of 50 cases patients with ovarian clear cell carcinoma (OCCC) and 103 cases with high-grade serous ovarian carcinoma (HGSOC), who were initially treated and completed standardized therapy in Affiliated Hospital of Qingdao University from January 2013 to December 2017.

Results: There were significant differences in age, gravidity (G > 1), chief complaint, with ovarian endometriosis, tumor diameter, unilateral or bilateral, cystic and solid tumor, CA125, HE4, CA199, lactate dehydrogenase (LDH), and FIGO stage between the two groups. The differences in the prognosis between OCCC patients and HGSOC patients with early stage (FIGO I–II) were not statistically significant. The 5-year overall survival and progression-free survival of OCCC patients were significantly worse than those of HGSOC patients with advanced stage (FIGO III–IV) (p < 0.05). FIGO stage and non-R0 resection were independent risk factors affecting the prognosis of patients with ovarian clear cell carcinoma, screening by Cox regression analysis. FIGO stage, the lowest value of CA125, and non-R0 resection were independent risk factors affecting the prognosis of patients with high-grade serous ovarian cancer.

Conclusions: The clinical characteristics and prognosis of OCCC are different from those of HGSOC. Ovarian clear cell carcinoma (OCCC) patients have a significantly worse prognosis than those with HGSOC in the advanced stage (FIGO Ⅲ–Ⅳ). Satisfactory tumor resection is an essential factor related to the prognosis of patients with OCCC and HGSOC.

Get Citation

Keywords

ovarian clear cell carcinoma; high-grade serous ovarian carcinoma; prognosis; risk factors; clinical characteristics

Supp./Additional Files (1)
Supplementary file
Download
61KB
About this article
Title

Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2022-12-06

Page views

145

Article views/downloads

108

DOI

10.5603/GP.a2022.0123

Pubmed

36477777

Keywords

ovarian clear cell carcinoma
high-grade serous ovarian carcinoma
prognosis
risk factors
clinical characteristics

Authors

Shixiang Dong
Fengsheng Yu
Yutong Liu
Xiao Yu
Xin Sun
Wenjie Wang
Yankui Wang

References (22)
  1. Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi, (Chinese). 2014; 43(10): 649–650.
  2. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998; 70(2): 255–258.
  3. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000; 92(18): 1534–1535.
  4. Oliver KE, Brady WE, Birrer M, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017; 147(2): 243–249.
  5. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008; 109(3): 370–376.
  6. Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989; 35(2): 199–203.
  7. Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer . Obstetrics & Gynecology. 1990; 72(2): 263–273.
  8. Kennedy AW, Markman M, Biscotti CV, et al. Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol. 1999; 74(1): 108–114.
  9. Leitao MM, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004; 28(2): 147–159.
  10. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006; 102(2): 285–291.
  11. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989; 32(1): 65–71.
  12. Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997; 176(3): 572–579.
  13. King CM, Barbara C, Prentice A, et al. Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. J Pathol. 2016; 238(2): 185–196.
  14. Park JY, Kim DY, Suh DS, et al. Significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma. Int J Gynecol Cancer. 2018; 28(1): 11–18.
  15. Kim HS, Choi HY, Lee M, et al. Systemic inflammatory response markers and CA-125 levels in ovarian clear cell carcinoma: a two center cohort study. Cancer Res Treat. 2016; 48(1): 250–258.
  16. Nakagawa N, Koda H, Nitta N, et al. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. Acta Med Okayama. 2015; 69(4): 227–235.
  17. Zhu J, Jiang L, Wen H, et al. Prognostic value of serum CA19-9 and perioperative CA-125 levels in ovarian clear cell carcinoma. Int J Gynecol Cancer. 2018; 28(6): 1108–1116.
  18. Fujino T, Watanabe T, Yamaguchi K, et al. The development of hypercalcemia in a patient with an ovarian tumor producing parathyroid hormone-related protein. Cancer. 2015; 70(12): 2845–2850, doi: 10.1002/1097-0142(19921215)70:12<2845::aid-cncr2820701221>3.0.co;2-f.
  19. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996; 60(3): 412–417.
  20. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(24): 3621–3627.
  21. Duska LR, Garrett L, Henretta M, et al. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010; 116(3): 374–377.
  22. Nasioudis D, Mastroyannis SA, Albright BB, et al. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. Gynecol Oncol. 2018; 150(1): 14–18.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl